December 15th, 2015

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

News releases from Applied Genetic Technologies Corporation

< Previous 1 2 3 4 Next >
AGTC to Participate in the H.C. Wainwright BioConnect 2021 Conference
Tickers AGTC
From GlobeNewswire News Releases
AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2020
Tickers AGTC
From GlobeNewswire News Releases
AGTC Reports Additional Positive Data from its Phase 1/2 Clinical Trial in Patients with X-Linked Retinitis Pigmentosa
Tickers AGTC
From GlobeNewswire News Releases
AGTC to Host Conference Call on November 11 at 8:00 am ET to Discuss XLRP 12-Month Data and Full 6-Month Data from Highest Dose Groups of its Ongoing Phase 1/2 Clinical Trial
Tickers AGTC
From GlobeNewswire News Releases
AGTC to Participate in Cantor Fitzgerald Virtual Panel: Key Considerations for Gene Therapy Manufacturing and Platforms
Tickers AGTC
From GlobeNewswire News Releases
AGTC to Present at Upcoming Virtual Conferences
Tickers AGTC
From GlobeNewswire News Releases
AGTC Joins the My Retina Tracker® Program as a New Scientific Collaborator
From GlobeNewswire News Releases
AGTC Provides Trial Design Update for its Phase 2/3 XLRP Clinical Trial, New Data on XLRP Higher Dose Group and Financial Results for the Fourth Quarter and Year Ended June 30, 2020
Tickers AGTC
From GlobeNewswire News Releases
AGTC to Participate at Upcoming Virtual Investor Conferences
Tickers AGTC
From GlobeNewswire News Releases
AGTC to Host Management Update on September 9 at 8:00 am ET to Discuss Planned Phase 2/3 XLRP Trial, Share Additional XLRP Data and Report Fourth Quarter and Fiscal Year End 2020 Financial Results
Tickers AGTC
From GlobeNewswire News Releases
AGTC Announces Publication of Preclinical Data that Support the Ongoing Clinical Development of Its XLRP Gene Therapy Program
Preclinical studies validate the transgene and dosing used in the ongoing Phase 1/2 clinical trial in patients with XLRP due to mutations in the RPGR gene 
Tickers AGTC
From GlobeNewswire News Releases
AGTC Formalizes Patient Advisory Council to Provide Insights and Guidance on Patient Perspectives for Pipeline Therapies
Tickers AGTC
From GlobeNewswire News Releases
AGTC to Present at the Wedbush PacGrow Virtual Healthcare Conference on August 11, 2020
Tickers AGTC
From GlobeNewswire News Releases
AGTC Announces Updated Development Plan for its X-Linked Retinitis Pigmentosa Clinical Program, Including Q1 2021 Start of Planned Phase 2/3 Trial
Tickers AGTC
From GlobeNewswire News Releases
AGTC Set to Join Russell 3000® and 2000® Indexes
Tickers AGTC
From GlobeNewswire News Releases
AGTC Announces Significant Productivity and Quality Enhancement To Its Proprietary Manufacturing Process
Tickers AGTC
From GlobeNewswire News Releases
AGTC to Present at BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference on June 23, 2020
Tickers AGTC
From GlobeNewswire News Releases
AGTC Launches Nationwide Mobile Vision Testing Program for Patients Enrolled in Its Ongoing Phase 1/2 Clinical Trials
Tickers AGTC
From GlobeNewswire News Releases
AGTC Announces Publication of Positive Preclinical Data that Provides Foundational Scientific Evidence for its Ongoing Clinical Program in Patients with X-Linked Retinitis Pigmentosa (XLRP)
Tickers AGTC
From GlobeNewswire News Releases
AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2020
Tickers AGTC
From GlobeNewswire News Releases
AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 13, 2020
Tickers AGTC
From GlobeNewswire News Releases
AGTC Announces Completion of Enrollment in All Adult Dose Groups of its Ongoing Phase 1/2 Clinical Trials in Patients with Achromatopsia
Tickers AGTC
From GlobeNewswire News Releases
AGTC Announces Completion of Enrollment in the Two Highest Dose Groups of its Ongoing Phase 1/2 Clinical Trial in Patients with X-Linked Retinitis Pigmentosa
Tickers AGTC
From GlobeNewswire News Releases
AGTC Announces Pricing of $32,500,000 Public Offering of Common Stock
Tickers AGTC
From GlobeNewswire News Releases
AGTC Announces Proposed Public Offering of Common Stock
Tickers AGTC
From GlobeNewswire News Releases
AGTC Reports Encouraging Interim Six-Month Data from the Dose Escalation Cohorts of its Ongoing Phase 1/2 Clinical Trials in Achromatopsia
Tickers AGTC
From GlobeNewswire News Releases
AGTC to Host Conference Call and Webcast on January 23 at 8:00 am ET to Discuss Achromatopsia Interim Six-Month Data from the Dose Escalation Cohorts of its Ongoing CNGB3 and CNGA3 Phase 1/2 Clinical
Tickers AGTC
From GlobeNewswire News Releases
AGTC Announces Agenda for R&D Day on January 28, 2020 in New York
Tickers AGTC
From GlobeNewswire News Releases
AGTC Reports Positive Six-Month Data from its Ongoing Phase 1/2 Clinical Trial in X-Linked Retinitis Pigmentosa
Tickers AGTC
From GlobeNewswire News Releases
AGTC to Host Conference Call and Webcast on January 9 at 8:00 am ET to Discuss X-Linked Retinitis Pigmentosa Interim Six-Month Data from the Dose Expansion Cohort of its Ongoing Phase 1/2 Clinical Tri
Tickers AGTC
From GlobeNewswire News Releases
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

3257 Dunmore Rd SE
Medicine Hat, AB T1B 3R2

[P] 403.527.1101
[F] 403.528.5696

Print Advertising: 403.528.5650
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2015 The Medicine Hat News, A Division of Continental Newspapers Canada Ltd.